Does Neoadjuvant Chemotherapy in Clinical T1–T2 N0 Triple-Negative Breast Cancer Increase the Extent of Axillary Surgery?

[1] Masuda N(2017)Adjuvant capecitabine for breast cancer after preoperative chemotherapy N Engl J Med. 376 2147-2159

[2] Lee SJ(2020)Pembrolizumab for early triple-negative breast cancer N Engl J Med. 382 810-821

[3] Ohtani S(2022)Event-free survival with pembrolizumab in early triple-negative breast cancer N Engl J Med. 386 556-567

[4] Schmid P(2023)Preoperative immunotherapy combined with chemotherapy for triple-negative breast cancer: perspective on the KEYNOTE-522 Study [published erratum appears in Ann Surg Oncol. 2023;30(6):3286] Ann Surg Oncol. 30 3166-3169

[5] Cortes J(2023)Early-stage triple-negative breast cancer journey: beginning, end, and everything in between Am Soc Clin Oncol Educ Book 43 2483-2493

[6] Pusztai L(1997)Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol. 15 4224-4237

[7] Schmid P(2001)Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902 J Clin Oncol. 19 778-785

[8] Cortes J(2008)Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27 [published correction appears in J Clin Oncol. 2008 Jun 1;26(16):2793] J Clin Oncol. 26 918-926

[9] Dent R(2023)National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial [published online ahead of print, 2023 Oct 20] Breast Cancer Res Treat 318 2159-2165

[10] Downs-Canner S(2017)Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial JAMA 41 1201-1108

[1] Masuda N(2017)Adjuvant capecitabine for breast cancer after preoperative chemotherapy N Engl J Med. 376 2147-2159

[2] Lee SJ(2020)Pembrolizumab for early triple-negative breast cancer N Engl J Med. 382 810-821

[3] Ohtani S(2022)Event-free survival with pembrolizumab in early triple-negative breast cancer N Engl J Med. 386 556-567

[4] Schmid P(2023)Preoperative immunotherapy combined with chemotherapy for triple-negative breast cancer: perspective on the KEYNOTE-522 Study [published erratum appears in Ann Surg Oncol. 2023;30(6):3286] Ann Surg Oncol. 30 3166-3169

[5] Cortes J(2023)Early-stage triple-negative breast cancer journey: beginning, end, and everything in between Am Soc Clin Oncol Educ Book 43 2483-2493

[6] Pusztai L(1997)Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol. 15 4224-4237

[7] Schmid P(2001)Preoperative chemotherapy in primary operable breast cancer: results from the European organization for research and treatment of cancer trial 10902 J Clin Oncol. 19 778-785

[8] Cortes J(2008)Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27 [published correction appears in J Clin Oncol. 2008 Jun 1;26(16):2793] J Clin Oncol. 26 918-926

[9] Dent R(2023)National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial [published online ahead of print, 2023 Oct 20] Breast Cancer Res Treat 318 2159-2165

[10] Downs-Canner S(2017)Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial JAMA 41 1201-1108